Date: 04/03/2025

By Moe Alsumidaie 

In this interview, Francisco Salva, CEO of Azitra, shared insights into the company’s innovative approach to treating skin diseases. Azitra is pioneering the use of engineered living organisms to address rare conditions like Netherton syndrome and ichthyosis vulgaris. By integrating advanced technologies, including artificial intelligence, Azitra hopes to set new dermatological treatment standards. Francisco discussed the company’s unique methodologies, current clinical trials, and challenges in this specialized field. Read the full article here https://www.clinicaltrialvanguard.com/executiveinterviews/azitra-therapeutics-revolutionizing-skin-disease-treatment/